Study Confirms That Raloxifene Reduces Risk of Invasive Breast Cancer in Postmenopausal Women

OncologyONCOLOGY Vol 15 No 5
Volume 15
Issue 5

The drug raloxifene (Evista) significantly reduces the risk of invasive breast cancer in postmenopausal women, according to the results of a large-scale study involving the University of Pittsburgh Graduate School of Public Health (GSPH) and

The drug raloxifene (Evista) significantly reducesthe risk of invasive breast cancer in postmenopausal women, according to the results of a large-scale study involving theUniversity of Pittsburgh Graduate School of Public Health (GSPH) and publishedin a recent issue of Breast Cancer Research and Treatment (65[2]:125-134, 2001).The Multiple Outcomes of Raloxifene Evaluation (MORE) trial measured the effectsof raloxifene, which has been approved by the US Food and Drug Administrationfor the prevention and treatment of osteoporosis, on breast cancer rates after 4years of follow-up. The results confirm the study’s preliminary findings,which where initially published in the Journal of The American MedicalAssociation (281:2189-2197, 1999).

"The MORE trial showed that raloxifene reduces the risk ofinvasive breast cancer by 72% in women who took this drug daily for 4years," said Jane Cauley, DrPH, lead author of the study report andassociate professor of epidemiology at the GSPH. "Specifically, raloxifenereduced the risk of estrogen-receptor-positive invasive breast cancer by 84%.This finding indicates that raloxifene is very effective at curbing thedevelopment of estrogen-fed breast tumors among older women with an averagebreast cancer risk."

MORE Results

MORE, a multicenter osteoporosis trial, involved 7,705postmenopausal women, with an average age of 66.5 years and a history ofosteoporosis. About 12% reported a family history of breast cancer. Participantswere randomly assigned to receive 60 or 120 mg of raloxifene per day or aplacebo. Neither investigators nor participants knew who received placebos andwho received raloxifene.

After 4 years, 39 cases of breast cancer were confirmed amongthe 5,129 women assigned to either dose of raloxifene, compared with 28 casesamong the 2,576 women assigned to the placebo. There were no significantdifferences in outcome between the group taking 60 mg of the drug and thosetaking 120 mg. Overall, raloxifene was well tolerated by participants.

Venous thromboembolism is a serious, although infrequentlyreported side effect of raloxifene. Other side effects associated withraloxifene include flu symptoms, hot flashes, leg cramps, endometrial cavityfluid and peripheral edema.

Longer-term effects of raloxifene on reducing the incidence ofbreast cancer in postmenopausal women will be evaluated in the ContinuingOutcomes Relevant to Evista (CORE) trial. 

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content